Asian Spectator

Men's Weekly

.

American Express Opens New Centurion Lounge at Tokyo’s Haneda Airport

NEW YORK, US - Media OutReach Newswire - 15 July 2025 - On July 16 American Express (NYSE: AXP) will open a new Centurion Lounge at Tokyo's Haneda Airport (HND), the busiest airport in Japan and one ...

Marshmello and Lana Del Rey to Headline Thursday Saturday Ni...

ABU DHABI, UAE, Oct. 2, 2019, /PRNewswire-Asianet/ -- Yas Marina Circuit and FLASH Entertainment have announced the international music superstars who will headline Thursday and Saturday nig...

4 HKTDC August Fairs, Chinese Medicine Conference Conclude

The Public Hall at the Food ExpoThe Trade Hall at the Food ExpoBeauty & Wellness Expo510,000 Visit Food, Tea, Beauty & Wellness and Home Delights EventsHONG KONG, Aug 20, 2018 - (ACN...

Upcoming UBBF 2022 Set to Delve into the Evolution to Ultra-Br...

BANGKOK, Oct. 21, 2022 /PRNewswire-Asianet/ -- From October 27 to 28 this year, the 8th Ultra-Broadband Forum (UBBF) co-hosted by the UN Broadband Commission and Huawei will be held in Bangk...

Markus Wiesner to Lead Heidrick Struggles' Consulting Busine...

HONG KONG and DUBAI, United Arab Emirates, March 9, 2021 /PRNewswire-AsiaNet/ -- Heidrick & Struggles ( https://c212.net/c/link/?t=0&l=en&o=3090318-1&h=2669421097&u=https...

Building Sustainable, Safe and Secure Rail Networks with COTS (Commercial-off-the-shelf) Solutions in Asia Pacific

SINGAPORE, Apr 9, 2021 - (ACN Newswire) - With nations now much more prepared in dealing with the pandemic with vaccinations, testing, and containment, Asia Pacific is slowly and surely get...

PolyU startups showcase innovation and entrepreneurial achievements at London Tech Week 2025

HONG KONG SAR - Media OutReach Newswire - 12 June 2025 - The Hong Kong Polytechnic University (PolyU) took part in the world-renowned London Tech Week 2025 held from 9 to 11 June in London...

CANOTWAIT_ by William Chan Launches Its Summer 2021 Collection

SHANGHAI, May 28, 2021 /PRNewswire-AsiaNet/ -- CANOTWAIT_, founded by William Chan, formally launched its 2021 summer collection in May 2021. The collection, themed "CANOTWAIT TO GO WILD", i...

CI T VTEX Drive Digital Transformation Effort Helping Carref...

BRISBANE, Australia,Aug.26,2021/PRNewswire-AsiaNet/-- - Replatforming from a legacy monolith solution to a modern SaaS e-commerce platform led to a 30% improvement in order conversions CI&am...

Eisai to Present Latest Data on Perampanel at the 73rd American Epilepsy Society Annual Meeting

Eisai to Present Latest Data on Perampanel at the 73rd American Epilepsy Society Annual Meeting

TOKYO, Nov 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States.

Thirty-Eight poster presentations will be given by Eisai at AES 2019, including results of a Phase III clinical study (FREEDOM / Study 342) to assess efficacy and safety of perampanel monotherapy for untreated patients from 12 to 74 years of age with partial-onset seizures and results of a retrospective Phase IV study (Study 506) of perampanel in real-world clinical care of patients with epilepsy. Including Investigator Initiated Studies, more than 40 scientific posters on perampanel will be presented at AES 2019.

Perampanel is a first-in-class AED and a once-daily tablet discovered at Eisai's Tsukuba Research Laboratories. In the United States and Europe, a new oral suspension formulation has been approved and is being marketed. The agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Perampanel is currently approved in countries around the world as adjunctive therapy for the treatment of partial-onset seizures (with or without secondarily generalized seizures) and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. Furthermore, perampanel is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older in the United States.

Eisai considers neurology including epilepsy, a therapeutic area of focus, and strives to deliver perampanel throughout the world in pursuit of our mission to provide "seizure freedom" to a greater number of patients living with epilepsy. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

About Fycompa (perampanel)

Fycompa is a first-in-class AED discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Fycompa is available in tablet form to be taken once daily orally at bedtime. In addition, an oral suspension formulation has been approved and marketed in the United States and in Europe. To date, Fycompa has been used to treat more than 270,000 patients worldwide across all indications.Fycompa is currently approved in more than 65 countries and territories, including the United States, Japan, China, in Europe and in Asia as an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. In addition, Fycompa has been approved in more than 60 countries, including the United States, Japan, in Europe and in Asia for treatment as adjunctive therapy for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In the United States, Fycompa is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older.

In Japan, a supplementary new drug application has been filed seeking approval of Fycompa for use as monotherapy for partial-onset seizures, treatment for partial-onset seizures in pediatric patients aged 4 years and older, as well as a fine granule formulation. In Europe, an application has been submitted seeking the additional approval of Fycompa for adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) or primarily generalized tonic-clonic seizures in pediatric patients with epilepsy.

Furthermore, Eisai is conducting a global Phase III clinical study (Study 338) for the agent in patients with seizures associated with Lennox-Gastaut syndrome.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2019 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Cara membuat prompt AI yang bagus biar produktif: tip dari ahli

FOTOSPLASH/Shutterstock“Apakah kamu mampu memanfaatkan AI dalam pekerjaan?”Kecerdasan buatan alias artificial intelligence (AI) sudah jadi bagian dari keseharian kita. Mulai dari ChatGPT, ...

Cara membahas masalah tanpa menimbulkan pertengkaran: Tip dari ahli

Pormezz / ShutterstockKita sebagai manusia memiliki perbedaan satu sama lain yang memengaruhi pendapat kita. Maka dari itu, ada kalanya kita tidak setuju dengan pendapat orang lain.Berbeda pendapat ka...

Diplomasi emosional: Bagaimana rasa marah dan takut dapat membentuk arah kebijakan global

Gambar Perdana Menteri Israel Benjamin Netanyahu (kiri) dan Pemimpin Tertinggi Iran Ayatollah Ali Khamenei di layar, merefleksikan perang antara Iran dan Israel.Mmiss.cabul/Shutterstock● Memanas...